Literature DB >> 18455284

Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.

Tom Lodewyck1, Jan J Cornelissen.   

Abstract

Allogeneic hematopoietic stem cell transplantation (alloSCT) is nowadays most frequently applied in patients with acute myeloid leukemia (AML). It combines chemoradiotherapy with immunotherapy, also known as the graft-versus-leukemia (GVL) effect. While it effectively reduces the relapse rate in patients, transplanted in remission, non-relapse mortality (NRM) may counterbalance that beneficial effect. As a result, alloSCT is generally associated with a modest gain in overall survival. Therefore, alloSCT may especially be applied in patients with a relatively high risk of relapse and a relatively low risk of NRM. Here, we discuss how recent findings that have identified and validated specific prognostic factors may affect our decision making for which category of AML-patients alloSCT may especially be indicated.

Entities:  

Mesh：

Year:  2008        PMID： 18455284     DOI： 10.1016/j.blre.2008.03.008

Source DB:  PubMed          Journal:  Blood Rev        ISSN： 0268-960X            Impact factor:   8.250


  6 in total

1.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.

Authors:  Matthias Stelljes; Dietrich W Beelen; Jan Braess; Maria C Sauerland; Achim Heinecke; Björna Berning; Hans J Kolb; Ernst Holler; Rainer Schwerdtfeger; Renate Arnold; Karsten Spiekermann; Carsten Müller-Tidow; Hubert L Serve; Gerda Silling; Wolfgang Hiddemann; Wolfgang E Berdel; Thomas Büchner; Joachim Kienast
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

3.  Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.

Authors:  Takeshi Kondo; Atsushi Yasumoto; Kotaro Arita; Jun-Ichi Sugita; Akio Shigematsu; Kohei Okada; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Yukari Takeda; Masato Obara; Satoshi Yamamoto; Tomoyuki Endo; Mitsufumi Nishio; Norihiro Sato; Junji Tanaka; Satoshi Hashino; Takao Koike; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2010-01-20       Impact factor: 2.490

4.  Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.

Authors:  Betul Oran; Uday Popat; Gabriella Rondon; Farhad Ravandi; Guillermo Garcia-Manero; Lynn Abruzzo; Borje S Andersson; Qaiser Bashir; Julianne Chen; Partow Kebriaei; Issa F Khouri; Ebru Koca; Muzaffar H Qazilbash; Richard Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-13       Impact factor: 5.742

5.  The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing Risks.

Authors:  Arash Jalali; Kamran Alimoghaddam; Mahmood Mahmoudi; Kazem Mohammad; Hojjat Zeraati; Seied Asadollah Mousavi; Babak Bahar; Mohammad Vaezi; Mohammad Jahani; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014-07-01

6.  Early lymphocyte recovery as a predictor of outcome, including relapse, after hematopoietic stem cell transplantation.

Authors:  Juliane Morando; Sérgio Costa Fortier; Ricardo Pasquini; José Zanis Neto; Carmem Maria Sales Bonfim
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.